HI
NMTR

Harbour Investments’s 9 Meters Biopharma NMTR Stock Holding History

Harbour Investments’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-265
Closed -$7K – 3896
2021
Q3 		$7K Hold
265
– – ﹤0.01% 2867
2021
Q2 		$6K Buy
+265
New +$6.51K ﹤0.01% 3012

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Harbour Investments's NMTR Position: Q4 2021 in Review

Harbour Investments sold out of 9 Meters Biopharma (NMTR) in Q4 2021, closing a stake of 265 shares — an estimated $7K sold.

Harbour Investments first reported a position in NMTR in Q2 2021 and held it in 2 quarters. The position peaked at $7K in Q3 2021. 104 funds tracked by Wall St. Rank hold NMTR as of Q4 2021.

  • Harbour Investments reported no remaining 9 Meters Biopharma position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 265 9 Meters Biopharma shares in Q4 2021, an estimated $7K.
  • Harbour Investments first reported a position in 9 Meters Biopharma in Q2 2021 and held it in 2 quarters.
  • Harbour Investments's 9 Meters Biopharma position peaked at $7K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.